Detalles de la búsqueda
1.
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.
Pharmacol Res
; 117: 406-415, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28089942
2.
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Eur Radiol
; 26(1): 32-42, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25956936
3.
Molecular features and clinical outcome of lung malignancies in very young people.
Future Oncol
; 11(8): 1211-21, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25832878
4.
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Oncologist
; 19(4): 344-5, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674875
5.
Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.
Am J Respir Crit Care Med
; 196(10): 1349-1350, 2017 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28910131
6.
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.
Cancer Treat Rev
; 119: 102602, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37481836
7.
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
Curr Oncol
; 30(5): 5072-5092, 2023 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37232842
8.
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Cancers (Basel)
; 15(19)2023 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37835473
9.
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations.
Cancers (Basel)
; 15(20)2023 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894445
10.
Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients.
Cancers (Basel)
; 15(18)2023 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37760521
11.
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Clin Lung Cancer
; 23(2): 108-115, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34952792
12.
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Front Oncol
; 12: 980765, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36033444
13.
Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study.
Transl Lung Cancer Res
; 11(5): 757-775, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35693285
14.
"Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer.
J Cancer Educ
; 26(2): 388-94, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20204572
15.
Interstitial pneumonitis in the COVID-19 era: a difficult differential diagnosis in patients with lung cancer.
Tumori
; 107(3): 267-269, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32842909
16.
Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey.
Front Oncol
; 10: 584612, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33163413
17.
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data.
Cancer Treat Rev
; 89: 102085, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32771858
18.
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model.
Front Oncol
; 10: 665, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32391282
19.
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
Clin Lung Cancer
; 21(1): 15-20, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31607443
20.
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.
Anticancer Res
; 40(1): 427-433, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31892597